AGN 0.00% 78.5¢ argenica therapeutics limited

Economic cost of stroke 2024 report, page-2

  1. 1,185 Posts.
    lightbulb Created with Sketch. 595
    I've read these over the past few years previously being a shareholder of Clinuvel who are trialling their drug for AIS. The economic impact is staggering not to mention the disruption and loss of quality of life for patients and families. Which is why I hold the view that even a small but discernible improvement in stroke patients via ARG-007 will have a good chance of being approved. I personally believe that the drug will offer more than a just a small improvement, but we have a long way to go.
 
watchlist Created with Sketch. Add AGN (ASX) to my watchlist
(20min delay)
Last
78.5¢
Change
0.000(0.00%)
Mkt cap ! $100.5M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 800 76.0¢
 

Sellers (Offers)

Price($) Vol. No.
78.5¢ 2022 2
View Market Depth
Last trade - 09.56am 01/11/2024 (20 minute delay) ?
AGN (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.